Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TEEMS: Etanercept + MTX vs MTX in Early RA
NCT03813771Phase 4Unknown
- Sponsor
- University of Leeds
- Start
- Mar 2019
- Primary completion
- Feb 2023
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of etanercept in rheumatoid arthritis (RA) (3 arms), sponsored by University of Leeds. Primary endpoint: Clinical Remission at 24 weeks (Arms A vs B). Status: unknown.
02
Drugs
etanercept
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT03813771.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03813771.